Rezolute rises after FDA talks on rare low blood sugar disease drug

Rezolute

24/03/2026 14:51

** Shares of biotech firm Rezolute RZLT.O rise 7% to $2.57

** Co says it met the FDA to discuss next steps for its experimental drug ersodetug for congenital hyperinsulinism, a rare condition that causes dangerously low blood sugar in children

** Says late‑stage trial showed the drug reduced low blood sugar episodes from baseline, but did not beat placebo on its main goal

** Says trial results were affected by patient behavior, as families may have changed how closely blood sugar was monitored

** Adds FDA acknowledged challenges of trials in this disease and said it will review full data before deciding on approval filing or additional studies

** Early data from an ongoing extension study showed continued benefits - RZLT

** RZLT fell ~52% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))